Trials / Unknown
UnknownNCT05751265
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer, Single-arm, Exploratory Clinical Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of advanced gastric cancer after first-line resistance
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab | Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks . Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle. |
| DRUG | 5Fu | Participants will receive 5-FU, 2.4 g/m2，bid，d1-d14，q3w |
| DRUG | Paclitaxel injection | Participants will receive paclitaxel 135 mg/m2 ivgtt q2w or 175mg/m2 q3w |
Timeline
- Start date
- 2023-07-01
- Primary completion
- 2024-06-01
- Completion
- 2025-06-01
- First posted
- 2023-03-02
- Last updated
- 2023-06-22
Source: ClinicalTrials.gov record NCT05751265. Inclusion in this directory is not an endorsement.